Surveillance for neuraminidase inhibitor resistance in human influenza viruses from Australia

Authors

  • Aeron C Hurt WHO Collaborating Centre for Reference and Research on Influenza, 45 Poplar Road, Parkville VIC 3052
  • Ian G Barr WHO Collaborating Centre for Reference and Research on Influenza, Melbourne, Australia
  • Christopher J Durrant WHO Collaborating Centre for Reference and Research on Influenza, Melbourne, Australia
  • Robert P Shaw WHO Collaborating Centre for Reference and Research on Influenza, Melbourne, Australia
  • Helen M Sjogren WHO Collaborating Centre for Reference and Research on Influenza, Melbourne, Australia
  • Alan W Hampson WHO Collaborating Centre for Reference and Research on Influenza, Melbourne, Australia

DOI:

https://doi.org/10.33321/cdi.2003.27.91

Keywords:

influenza, neuraminidase inhibitors, oseltamivir carboxylate, zanamivir

Abstract

Two hundred and forty-five human influenza A and B viruses isolated in Australia between 1996 and 2003 were tested for their sensitivity to the NA inhibitor drugs, zanamivir and oseltamivir using a fluorescence-based neuraminidase inhibition assay. Based on mean IC50 values, influenza A viruses (with neuraminidase subtypes N1 and N2) were more sensitive to both the NA inhibitors than were influenza B strains. Influenza A viruses with a N1 subtype and influenza B strains both demonstrated a greater sensitivity to zanamivir than to oseltamivir carboxylate, whereas influenza A strains with a N2 subtype were more susceptible to oseltamivir carboxylate. A comparison of IC50 values for viruses isolated before and after the release of the NA inhibitors in Australia, found there was no significant difference in the sensitivity of strains to either neuraminidase inhibitor and none of the isolates tested showed clinically significant resistance. Commun Dis Intell 2003;27:542-547.

Downloads

Download data is not yet available.

References

McKimm-Breschkin JL. Neuraminidase inhibitors for the treatment and prevention of influenza . Expert Opin Pharmacother 2002;3:103-112.

Stiver G. The treatment of influenza with antiviral drugs. CMAJ 2003;168:49-56.

Colman PM. Influenza virus neuraminidase: structure, antibodies, and inhibitors. Protein Sci 1994;3:1687-1696.

Varghese JN, Laver WG, Colman PM. Structure of the influenza virus glycoprotein antigen neuraminidase at 2.9 A resolution. Nature 1983;303:35-40.

Zambon MC. Epidemiology and pathogenesis of influenza. J Antimicrob Chemother 1999;44 Suppl B:3-9.

Belshe RB, Smith MH, Hall CB, Betts R, Hay AJ. Genetic basis of resistance to rimantadine emerging during treatment of influenza virus infection. J Virol 1988;62:1508-1512.

McKimm-Breschkin JL. Resistance of influenza viruses to neuraminidase inhibitors-a review. Antiviral Res 2000;47:1-17.

Gubareva LV, Matrosovich MN, Brenner MK, Bethell RC, Webster RG. Evidence for zanamivir resistance in an immunocompromised child infected with influenza B virus. J Infect Dis 1998;178:1257-1262.

Roberts NA. Treatment of influenza with neuraminidase inhibitors: virological implications. Philos Trans R Soc Lond B Biol Sci 2001;356:1895-1897.

McKimm-Breschkin JL, Trivedi T, Hampson A, Hay A, Klimov A, Tashiro, et al. Neuraminidase sequence analysis and susceptibilities of influenza virus clinical isolates to zanamivir and oseltamivir. Antimicrob Agents Chemother 2003;47:2264-2272.

Potier M, Mameli L, Belisle M, Dallaire L, Melancon SB. Fluorometric assay of neuraminidase with a sodium (4-methylumbelliferyl-alpha-D-N-acetylneuraminate) substrate. Anal Biochem 1979;94:287-296.

Barnett JM, Cadman A, Gor D, Dempsey M, Walters M, Candlin A, et al. Zanamivir susceptibility monitoring and characterization of influenza virus clinical isolates obtained during phase II clinical efficacy studies. Antimicrob Agents Chemother 2000;44:78-87.

Zambon M, Hayden G, Global Neuraminidase Inhibitor Susceptability Network. Position statement: global neuraminidase inhibitor susceptibility network. Antiviral Res 2001;49:147-156.

Boivin G, Goyette N. Susceptibility of recent Canadian influenza A and B virus isolates to different neuraminidase inhibitors. Antiviral Res 2002;54:143-147.

Jackson HC, Roberts N, Wang ZM, Belshe R. Management of influenza: Use of new antivirals and resistance in perspective. Clin.Drug Invest 2000;20:447-454.

Gubareva LV, Robinson MJ, Bethell RC, Webster RG. Catalytic and framework mutations in the neuraminidase active site of influenza viruses that are resistant to 4-guanidino-Neu5Ac2en. J Virol 1997;71:3385-3390.

Tai CY, Escarpe PA, Sidwell RW, Williams MA, Lew W, Wu H, et al. Characterization of human influenza virus variants selected in vitro in the presence of the neuraminidase inhibitor GS 4071. Antimicrob Agents Chemother 1998;42:3234-3241.

Wetherall NT, Trivedi T, Zeller J, Hodges-Savola C, McKimm-Breschkin JL, Zambon M, et al. Evaluation of neuraminidase enzyme assays using different substrates to measure susceptibility of influenza virus clinical isolates to neuraminidase inhibitors: report of the Neuraminidase Inhibitor Susceptibility Network. J Clin Microbiol 2003;41:742-750.

Peng AW, Milleri S, Stein DS. Direct measurement of the anti-influenza agent zanamivir in the respiratory tract following inhalation. Antimicrob Agents Chemother 2000;44:1974-1976.

Tisdale M. Monitoring of viral susceptibility: new challenges with the development of influenza NA inhibitors. Rev Med Virol 2000;10:45-55

Downloads

Published

31/12/03

How to Cite

Hurt, Aeron C, Ian G Barr, Christopher J Durrant, Robert P Shaw, Helen M Sjogren, and Alan W Hampson. 2003. “Surveillance for Neuraminidase Inhibitor Resistance in Human Influenza Viruses from Australia”. Communicable Diseases Intelligence 27 (December):542-47. https://doi.org/10.33321/cdi.2003.27.91.

Issue

Vol. 27 (2003)

Section

Original article

Categories

License

Copyright (c) 2003 Communicable Diseases Intelligence

Creative Commons License

This work is licensed under a Creative Commons Attribution-NonCommercial-NoDerivatives 4.0 International License.

Most read articles by the same author(s)

1 2 > >>